Permanent neonatal diabetes in INS(C94Y) transgenic pigs

Diabetes. 2013 May;62(5):1505-11. doi: 10.2337/db12-1065. Epub 2012 Dec 28.

Abstract

Mutations in the insulin (INS) gene may cause permanent neonatal diabetes mellitus (PNDM). Ins2 mutant mouse models provided important insights into the disease mechanisms of PNDM but have limitations for translational research. To establish a large animal model of PNDM, we generated INS(C94Y) transgenic pigs. A line expressing high levels of INS(C94Y) mRNA (70-86% of wild-type INS transcripts) exhibited elevated blood glucose soon after birth but unaltered β-cell mass at the age of 8 days. At 4.5 months, INS(C94Y) transgenic pigs exhibited 41% reduced body weight, 72% decreased β-cell mass (-53% relative to body weight), and 60% lower fasting insulin levels compared with littermate controls. β-cells of INS(C94Y) transgenic pigs showed a marked reduction of insulin secretory granules and severe dilation of the endoplasmic reticulum. Cataract development was already visible in 8-day-old INS(C94Y) transgenic pigs and became more severe with increasing age. Diabetes-associated pathological alterations of kidney and nervous tissue were not detected during the observation period of 1 year. The stable diabetic phenotype and its rescue by insulin treatment make the INS(C94Y) transgenic pig an attractive model for insulin supplementation and islet transplantation trials, and for studying developmental consequences of maternal diabetes mellitus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Substitution
  • Animals
  • Animals, Genetically Modified
  • Cataract / complications
  • Cataract / pathology
  • Cataract / physiopathology
  • Diabetes Complications / pathology*
  • Diabetes Complications / physiopathology
  • Diabetes Mellitus / drug therapy
  • Diabetes Mellitus / genetics*
  • Diabetes Mellitus / pathology*
  • Diabetes Mellitus / physiopathology
  • Diabetic Nephropathies / pathology
  • Diabetic Nephropathies / physiopathology
  • Diabetic Neuropathies / pathology
  • Diabetic Neuropathies / physiopathology
  • Disease Models, Animal*
  • Endoplasmic Reticulum / metabolism
  • Endoplasmic Reticulum / ultrastructure
  • Gene Expression Regulation
  • Hyperglycemia / prevention & control
  • Hypoglycemic Agents / therapeutic use
  • Insulin / genetics*
  • Insulin / metabolism
  • Insulin / therapeutic use
  • Insulin Secretion
  • Insulin-Secreting Cells / metabolism
  • Insulin-Secreting Cells / ultrastructure
  • Mutation*
  • RNA, Messenger / metabolism
  • Secretory Vesicles / metabolism
  • Secretory Vesicles / ultrastructure
  • Severity of Illness Index
  • Sus scrofa

Substances

  • Hypoglycemic Agents
  • Insulin
  • RNA, Messenger

Supplementary concepts

  • Diabetes Mellitus, Permanent Neonatal